NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

976.75 5.65 (0.58%)

25.09% Fall from 52W High

73,190 NSE+BSE Volume

NSE 17 Sep, 2025 12:59 PM (IST)

19,199.3

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

24 Jan 2020

976.75

0.58%

Alembic Pharmaceuticals Ltd: Results Outperform Due to Sartan Supply Opportunities

Hold: Alembic Pharmaceuticals Ltd.

Target

Karvy

In Q3FY20, total revenues of Alembic Pharma increased by 18.7percent YoY toRs. 12.1 bn.

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

23 Jan 2020

976.75

0.58%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Specialty contribution in the domestic branded space increased to 63% in FY19 from 54% in FY14. However, despite having an established set up, growth (FY14-19 CAGR of 5%) has lagged the industry growth curve. The company is consciously focusing on this aspect with focus on overhauling of distribution channels (defocusing on trade generics). Overall, we expect...

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

22 Jan 2020

976.75

0.58%

Niche opportunity in US drives earnings

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

22 January 2020 by International Formulations (+48% YoY), supported by the US (+61% YoY; 43% of sales) and Non-US (+15% YoY; 12% of sales) segments. However, muted growth in India (1% YoY; 30% of sales) and API business (-14% YoY; 15% of sales) dragged growth to some extent. Gross margin shrank marginally by 30bp YoY to 75% due to the change in 25%) led by lower employee cost (-70bp YoY) and other expenses (-470bp YoY), partly offset by higher R&D; expense (+110bp YoY). EBITDA increased PAT grew at a higher rate of 38% YoY (v/s EBITDA growth) to INR2.3b (our Sartans-led opportunity is expected to continue for the next 3-6 months. ALPM incurred capex of INR5.5b in 9MFY20, of which INR1.8b was in 3QFY20. As most sites would be ready by FY20, it would likely incur maintenance-related capex of INR3-3.5b annually. Gross debt stood at INR14.1b and cash at INR590m at end-3QFY20.

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

22 Jan 2020

976.75

0.58%

Alembic Pharma (BUY): Good beat we raise EPS estimates by 5-7%

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Alembic Pharma (ALPM) reported a 15% EBITDA beat in Q3 driven by a sales beat and stable opex despite an additional expense hit from Aleor-Derma unit commercialisation.

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

10 Dec 2019

976.75

0.58%

First Light | [Initiation] Alembic Pharma, Weekly Eco Wrap

Buy: Alembic Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

ALPM: Entering into new multi-year earnings cycle initiate with BUY; Weekly Eco Wrap: Spotlight on Fed and ECB

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

09 Dec 2019

976.75

0.58%

[INITIATION] Alembic Pharma (BUY): Entering into new multi-year earnings cycle initiate with BUY

Buy: Alembic Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

Alembic Pharma (ALPM) has underperformed the midcap and Sensex indices since 2015 due to subdued earnings. This cycle should reverse in the next 3-4 years.

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

04 Nov 2019

976.75

0.58%

Alembic Pharmaceuticals

Buy: Alembic Pharmaceuticals Ltd.

Monarch Networth Capital Limited

ALPM's secret sauce remains its ability to scale with judicious capital allocation and ALPM IN 8.0 -1.2 -7.8 Daily Vol. (3M Avg.) execution prowess to capitalize on shortages and limited competition products. NIFTY st 3.5 1.1 14.4 *as on 1 November 2019; Source: Bloomberg, MNCL Research Moreover, domestic business, presently undergoing a strategic reset, should revert...

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

25 Oct 2019

976.75

0.58%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

Target

Karvy

Revenues and margins outperform in US due to supply shortages

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

31 Jul 2019

976.75

0.58%

Alembic Pharmaceuticals: Lower revenue growth due to muted performance in domestic formulations and ROW market

Hold: Alembic Pharmaceuticals Ltd.

Target

Karvy

In Q1FY20, total revenues of Alembic Pharma increased by 10% YoY to Rs 9.5 bn (below our estimates Rs 9.8 bn).

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

30 Jul 2019

976.75

0.58%

Alembic Pharma (1QFY20): Unappealing, ex-US. Maintain NEUTRAL

Neutral: Alembic Pharmaceuticals Ltd.

Target

HDFC Securities

1QFY20's sharp improvement in operating performance was driven by short-term opportunities in the US, which will not persist. Sustainable growth relies upon approvals for lucrative onco-injectables and derma products, which will reflect in revenues only by FY22E. Meanwhile in India, the co is consistently underperforming the broader market. Hence, we lack visibility on revenue growth above 13% CAGR over FY19-21E. Additionally, incremental stress on margins (-100bps over FY19-21E) will restrict PAT CAGR to 11%. Valuations, too, remain unsupportive at 21.1/16.8x FY20/21E P/E. We maintain NEUTRAL on ALPM following a miss on our revenue estimates, while profitability was higher than expectation. Growth across segments was muted, barring the US. Our TP is unchanged at Rs 570 (18x FY21E EPS).

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Is Alembic Pharmaceuticals Ltd. worth buying?

239 Votes:

Buy 84.1%

Sell 7.95%

Hold 7.95%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf